Skip to main content
Equibles
STRO logo

STRO · Sutro Biopharma, Inc. · Metrics

Track STRO — free

Use STRO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research STRO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.20 -0.74 (-7.44%) At close · Nov 5
Russell 2000 member Rebalance outlook locked
Market Cap
$153.71M
Shares
16.58M
Volume · Nov 5 771.86K Avg daily vol (3M) 319.6K

STRO metrics

67 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.20
Market cap
$153.71M

Price action

20 metrics
Price change (1W)
+7.0%
Price change (30D)
-31.2%
Price change (3M)
-60.4%
Price change (6M)
-73.6%
Price change (YTD)
-14.1%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
83.7%
Annualized volatility (3M)
72.0%
Beta
1.2
RSI (14D)
34.8
Price vs SMA 50
-32.4%
Price vs SMA 200
-56.7%
Avg volume (3M)
310,169
Relative volume
0.5
Average dollar volume
$4.96M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
16.58M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.5×
reciprocal yield 28.8%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-113.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.6×
reciprocal yield 171.7%
EV / revenue historical average (5Y)
3.9×
reciprocal yield 25.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
—
Operating margin
-319.6%
Trailing 12 months
Net margin
-395.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$146.05M
Net income (TTM)
−$180.64M
Trailing 12 months
Diluted EPS (TTM)
$-17.33
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$4.20
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-14.19
EBITDA per diluted share (TTM)
$-13.61
Net income per diluted share (TTM)
$-17.39
Operating cash flow per diluted share (TTM)
$-13.11
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$13.65
Stock compensation per diluted share (TTM)
$0.62
Book value per share
$-15.43

Growth

11 metrics
Revenue growth YoY
-84.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$45.70M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+94.7%
Year over year · more shares
Revenue CAGR (3Y)
+14.8%
Revenue CAGR (5Y)
+19.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-92.9%
Debt / equity
—
Current ratio
3.3
EBITDA (TTM)
−$139.99M
Free cash flow (TTM)
—
Quick ratio
3.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$54.34M
Total assets
$194.46M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$145.17M
Capital expenditures (TTM)
$2.23M
R&D (TTM)
$144.74M
SG&A (TTM)
—
Stock compensation (TTM)
$6.78M
R&D / revenue
316.7%
Stock compensation / revenue
14.8%

Ownership (13F)

9 metrics
13F filers
100
13F filer change QoQ
+22
Institutional ownership
99.5%
Conviction holders (share of 13F filers)
5.0%
Crowding (high-turnover and private-fund holders)
60.2%
Private-fund adviser ownership
59.4%
Active holders' share change QoQ
+2.3%
Holder tenure
8.3
Price vs estimated holder cost
+47.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.8%

Short interest

3 metrics
Short interest
11.8%
Latest settlement · 6.3 days to cover
Days to cover
6.3d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1382101 CUSIP 869367201 13F (30d) 31 filings 19 filers Visit website Investor relations